



Biovision Catalyzer 13-14 APRIL 2016



BIOVISION The World Life Sciences Forum



One line pitch:

Biopharmaceuticals to treat 70% of the patients that still do not respond to conventional immunotherapy in cancer (anti-checkpoint therapy).

Market Analysis:

- Immunotherapy is a major breakthrough in oncology within the last few years. In 2015, Nivolumab (anti-PD-1 checkpoint) is priced 100'000\$ per patients and Ipilimumab (anti-CTLA-4 checkpoint) around 150'000\$. The overall anti-checkpoint market size is estimated in 2015 around 2B\$. However, these treatments work for approximately 30% of the patients, so the other 70% of the patients represents a huge market. - Aduro Biotech concluded with Novartis a 750mio\$ deal (200mio\$ upfront) on a preclinical synthetic STING agonist which works for patients that do not respond yet to anti-checkpoint therapy. It is a signal that the market is important.

Business Proposition:

The STING pathway is known to induce an activation of innate immunity, and a lymphocytes T-CD8 response against tumor cells (which is lacking for non-responding patients under anti-checkpoint therapy). Stimunity's technology is based on a Virus-Like Particle (VLP) which encapsulates inside the cGAMP, a molecule that is known to be the most efficient STING ligand to date. The VLP is the ideal delivery system that efficiently fuses with the cell membranes and delivers intracellularly the ligand cGAMP. In vivo results show excellent activation of the STING pathway, T-CD8 production, and anti-tumoral response.

Competitive Advantage:

Two advantages: - Highly efficient in tumors with a very low quantity of compound. Thus, the compound has a large therapeutic window with possibility to reduce side effects (very severe in immunotherapy) or increase the "boosting" effect (without too many side effects). - Cell targeting system. VLPs allow to design a drug that can be administered systemically, intravenous for example (unlike the competition on cGAMP/STING that can only administrate intra-tumorally).

Investment Attractiveness:

- A "low-risk" strategy by being best-in-class compound and following the only competitor that is 2 years ahead. - Clear market valuation (Aduro/Novartis deal in 2015 for 200mio\$ upfront). - No competition for the systemic delivery of cGAMP.

IP Situation:

A US patent application was filled end of 2014 and is covering any product based on any VLP which encapsulates cGAMP.

COMPANY PROFILE

- **Website:**
stimunity.com
- **Activity:** Biotech
- **Contact:**
CARLIOZ Sylvain
sylvain.carlioz@curie.fr
- **Location:**
24, RUE DU FAUBOURG
SAINT JACQUES
75014
France
- **Founded in:** 24/02/2016
- **Employees:** 2
- **Management:**
Manel Nicolas
Scientific Advisor
Carlioz Sylvain
CEO
- **Financial information (€):**
 - **Company stage:**
Seed
 - **Capital raised to date:**
 - **Monthly burn rate:**
 - **Capital seeking and date:**
5mio€
- **Investors:**
- **Referred by:**
Florent Gros, Novartis Venture Fund